Prescription Drug Coverage Through an HSA vs a Drug Plan

Canada's public health system pays for doctors and hospitals, but not for the pills most people pick up at the pharmacy. Canada's public system leaves working-age adults without drug coverage unless an employer steps in. In most of the country, prescription access has become a job benefit. Employers who skip this piece of the benefits puzzle aren't being neutral. Their employees end up paying full price for blood pressure pills, antidepressants, insulin, and the rest, and that cost raises turnover, slows hiring, and leaves a workforce more worn down than it should be. Two very different tools have grown up to close this gap: a Health Spending Account, built as a Private Health Services Plan under the Income Tax Act, and a traditional group drug plan, built as an insurance product. They solve the same problem through opposite designs, and that design gap is what the rest of this piece is about.

HSA reimbursement for a prescription claim

A Health Spending Account works on a simple idea: the employer sets aside a dollar amount for each employee every year, and the employee draws against it for medical costs the CRA allows, prescriptions included. There's no insurer deciding what counts, no co-pay at the register, and no list of approved drugs to check against. The employee pays for the prescription, saves the receipt, submits it, and gets paid back out of the account.

The tax treatment is what makes this worth paying attention to. Because the plan qualifies as a Private Health Services Plan under the Income Tax Act, money paid out to the employee is tax-free in the employee's hands, and the employer can deduct it as a business cost. Frontier HSA, a pay-as-you-go health benefits platform for incorporated Canadian businesses, lets employers set an annual prescription budget per employee and reimburse any CRA-eligible drug expense, including dispensing fees, antibiotics, insulin, and vaccines, with no formulary restrictions, as long as employees upload their receipts through the platform.

Prescriptions sit near the top of the list of things people claim through an HSA, and the range is wide: antibiotics, blood pressure medication, antidepressants, insulin, vaccines, any drug a licensed practitioner prescribes and a pharmacist fills. Dispensing fees count too. Over-the-counter drugs don't qualify unless a physician prescribed them. There's no category the drug has to fall into and no tier it has to clear. If the CRA says the expense is eligible and the employee has a prescription, the claim goes through.

Quebec employers need to watch one wrinkle. HSA contributions aren't taxable federally, but Quebec treats them as a taxable provincial benefit under RL-1 Box J, so a business with Quebec staff has to build that into how it sets up the plan.

All of this runs against one hard stop: the annual credit. Once an employee has used up the dollar amount the employer set aside for the year, the account stops paying, no matter what's left on the prescription bill. That ceiling is the first thing to understand about how an HSA differs from an insurance-based drug plan, and it shapes everything compared in the sections ahead.

How a traditional group drug plan covers prescriptions differently

A group drug plan starts from an entirely different premise. Instead of a dollar credit the employee draws down, it's an insurance contract: the insurer agrees to pay a set percentage of prescription costs, up to a defined annual maximum, for drugs that appear on its formulary. The formulary, not the CRA's eligible expense list and not the employee's own judgment, decides what gets covered and at what rate. Basic extended health plans often come with lower prescription maximums; more comprehensive plans raise those caps and loosen the restrictions, usually for a higher premium.

Premiums work on pooling. The employer pays into the plan every month whether or not anyone files a claim that month, and the insurer resets the price at renewal based on how much the group claimed over the past year. That makes the structure predictable (a monthly bill) even though the dollar amount isn't fixed year to year.

Quebec changes the calculus here too. RAMQ requires every resident to carry either its public prescription drug plan or equivalent private coverage, so any group plan offered to Quebec employees effectively has to include drug coverage as a matter of law, not just design preference.

One practical edge drug plans hold over HSAs is direct billing. The pharmacy bills the insurer directly, and the employee pays only the co-pay at the counter, no advance payment, no waiting on a reimbursement to land in a bank account. For employees juggling several prescriptions a month, that convenience matters.

None of this makes a drug plan a lesser version of an HSA. It's a tool built to pool risk across a group and manage a defined category of spending, and it does that job well. The two models simply answer different questions, and that difference becomes clear once real prescription costs enter the picture.

Outcomes for the same prescription dollar under each model

Take a family with steady, moderate prescription needs each year, nothing dramatic, just regular refills. Run that through an HSA: the family gets reimbursed in full, no co-pay, no formulary check, and the employer pays only what gets claimed. In a low-claim year, the employer isn't out any money it didn't actually use. Run the same family through a group drug plan and the employer has already paid premiums whether or not that family filed a single claim; the plan can end up costing more for the same outcome in years when claims stay light.

Predictability points in opposite directions for the two models. An employer funding an HSA knows the maximum it will spend, set once a year, with no surprise at renewal. An employer carrying a group drug plan is tied to whatever the insurer prices at renewal, and that number can jump after a year with heavier claims across the group.

The HSA's limit is also its weak spot. Once the year's credit runs out, the employee covers whatever prescription cost is left, with nothing behind it. A drug plan doesn't have that same hard wall, but it has its own version: the formulary. A plan might exclude a newly approved drug entirely, or cover only the generic version and leave the brand-name option unpaid. An HSA sidesteps that problem by covering any CRA-eligible prescription automatically, formulary or not.

GLP-1 drugs like Ozempic and Wegovy show this tension clearly. A group drug plan's coverage of these drugs depends on the carrier's current rules for diabetes treatment versus weight-loss use, and that line shifts as carriers update policy. An HSA doesn't ask the question: if the employee has a valid prescription, the claim qualifies.

The one place a drug plan still wins cleanly for the employee is paperwork. Direct billing means no receipts to track, no forms to submit. An HSA claim requires keeping proof: the practitioner's name, the date, the service, the amount. For an employee who'd rather not manage that, a drug plan is simpler day to day, even if it costs the employer more in flat premium terms.

Rising specialty drug costs and the limits of each model

Specialty and ultra-high-cost drugs are where both models get tested hardest, and neither comes through unscathed. TELUS Health's 2026 Drug Data Trends & National Benchmarks report found that specialty drugs, defined by a high annual treatment cost threshold, made up more than a third (33.9 per cent) of total eligible private drug spend in 2025, even though only a small slice of claimants actually used them. Nearly all the cost sits with a tiny number of people.

Ultra-high-cost therapies push average annual eligible amounts per claimant well into six figures for the people who need them, a scale no standard HSA credit was ever built to cover. A few thousand dollars a year in HSA credit does essentially nothing against a drug that costs tens of thousands annually. Once that balance is gone, the employee is left paying most of the bill out of pocket.

Group drug plans don't escape this pressure either. A single high-cost claimant can push premiums up for the whole group at renewal, and stop-loss thresholds, the point at which reinsurance kicks in, are getting triggered more often, sometimes on claims running into the hundreds of thousands of dollars. Carriers have one lever an HSA doesn't: biosimilar switching, steering a claimant toward a lower-cost biosimilar once one becomes available. Inside a pure HSA, the employee picks the drug that gets dispensed, and the plan has no way to redirect that choice.

The honest read here is that specialty drugs expose a limit in both models at once. An HSA simply can't absorb a six-figure claim, and a drug plan absorbs it but pays for that protection through premium volatility across the whole group. As costs rise, the HSA's lack of formulary gatekeeping turns into a real structural advantage in one narrow sense: Frontier HSA reimburses any prescribed drug that meets CRA eligibility rules regardless of cost or therapeutic category, while a traditional drug plan has to manage its own risk exposure, which can mean tighter coverage or higher premiums down the line. Neither fact erases the other. Both point toward the same conclusion: one tool alone isn't built to handle the full range of prescription risk a workforce can produce.

Combining an HSA with a base drug plan

The response many employers have landed on runs a base group drug plan for large and catastrophic claims, layered with an HSA to cover the gaps and the costs the drug plan's formulary won't touch. That combination gives a small business a predictable base cost and gives employees coverage that reaches further than either tool manages alone.

The typical version looks like this: the group drug plan pays its set co-insurance share of an eligible prescription, and the employee submits whatever's left, the remaining out-of-pocket gap, through the HSA. The drug plan carries the size of the risk; the HSA mops up the rest. The same structure solves the formulary gap from the section above too: a drug the group plan won't cover can still get reimbursed through the HSA, as long as it's CRA-eligible and the employee has a prescription.

For a small business with no existing coverage at all, a standalone HSA is a real place to start, not a lesser substitute for insurance. It skips the minimum employee counts, the medical questionnaires, and the annual underwriting that come with a group plan, and it still delivers tax-free prescription reimbursement for everyday needs. This structural gap, where Canada's public system covers physicians and hospitals but leaves prescriptions to private employer funding, is why some incorporated Canadian businesses choose Health Spending Accounts as an alternative to group drug plans, giving them direct control over whether and how to fund prescription coverage.

The cost logic of the hybrid setup is straightforward: the employer sets the HSA credit and knows that number cold, while the drug plan premium moves, and its swings are smaller because the HSA is already absorbing the smaller claims and the gaps instead of pushing everything through the insured plan. None of this makes the standalone HSA a compromise. It's a different design, one that leaves catastrophic drug exposure unaddressed on its own, and a business should go in knowing that before the worst possible moment.

Choosing between these structures

The right structure for a given business comes down to a handful of practical questions: how big the workforce is, how much budget predictability matters, what the health profile of the team looks like, and whether catastrophic drug exposure is a real risk worth insuring against or a routine-access problem that a fixed credit can solve on its own.

A standalone HSA tends to fit best for a very small workforce, where group plan minimums or underwriting requirements get in the way before the business even gets started. It also fits a team with varied health needs, where a single formulary would leave a good number of employees underserved no matter which plan the employer picked. And it fits an employer whose top priority is a fixed, known annual cost with nothing sprung on them at renewal, serving employees whose prescription needs are mostly routine.

A group drug plan, or a hybrid built around one, makes more sense once the workforce includes people with chronic conditions or known high-cost drug needs, since pooled insurance is what actually protects against a claim too large for any employee to absorb alone. Direct billing also matters for employers who want to cut down on the paperwork employees deal with day to day. Quebec coverage is its own consideration, since RAMQ equivalence is a legal requirement, not just a design choice. And any employer that sees real catastrophic drug risk sitting in its workforce, rather than a hypothetical one, has good reason to want that risk pooled through insurance instead of carried by individual employees.

Frontier HSA is built specifically for the standalone or HSA-first path: no setup fee, no annual fee, an 8 per cent administration fee charged only on approved claims, digital receipt submission with reimbursement by EFT, coverage across the full range of CRA-eligible medical expenses including prescriptions, and support for employees and their dependants. It's a transparent, pay-as-you-go setup aimed at small Canadian businesses that want to offer real prescription coverage without taking on the complexity of a full insurance contract. For employers seeking that kind of transparency and predictability, the appeal is in the simplicity: no monthly premiums, no renewal tied to claims experience, no formulary surprises, just a fixed annual budget per employee that the business sets and controls, which makes the true cost of offering prescription coverage much easier to forecast. For a business that already carries a group drug plan, layering an HSA on top turns employee out-of-pocket costs, co-pays, dispensing fees, prescriptions the formulary won't cover, into tax-free reimbursements, which stretches the value of both tools further than either reaches alone.

CRA's carry-forward rules under IT-529 ¶16 allow either unused credits or unused eligible expenses, but not both, to roll forward for up to twelve months, one plan year. An employee expecting a heavier prescription year ahead should understand that rule well before the year starts, so a claim gets timed to use the balance before the calendar cuts it off.